Strategic Partnership Forge Therapeutics has a history of forming strategic collaborations with industry players (Roche, Basilea Pharmaceutica, Evotec) and a merger with Blacksmith Medicines. This indicates openness to co-development and licensing deals, presenting opportunities to propose joint development, asset licensing, or co-funding arrangements to accelerate metalloprotein inhibitor programs.

Metalloenzyme Focus The company specializes in metalloprotein targets by focusing on metal active sites, a niche with potential demand from biotechs and pharma seeking novel antibiotic, anti-infective, or oncology assets. Sales outreach can tailor solutions around metalloprotein screening services, assay development, or collaborative discovery programs leveraging Forge's unique approach.

Funding and Scale With a funding level around thirty million and modest revenue, Forge is positioned for discovery-stage partnerships or milestone-rich collaborations rather than purely product sales. Propose value through early-stage discovery services, platform access, or option-based deals that align with their funding trajectory.

Leadership and Talent Recent executive appointments and leadership in CSO role signal science-driven strategy and potential for high-impact R&D programs. Engage at the scientific leadership level to discuss strategic roadmaps, co-development opportunities, and technical collaborations that align with their translational timelines.

Global Partner Network Past and ongoing partnerships with Roche, Basilea, and Evotec point to a strong channel for expanding collaborations in antibiotics and infectious disease spaces. Leverage this network to propose multi-party partnerships, regional co-development, or licensing assets that fit their metalloprotein inhibitor pipeline.